NV, a global provider of high-quality drug development and delivery solutions to the pharmaceutical
and biopharma sectors, has acquired Roche’s active pharmaceutical
ingredients (APIs) manufacturing facility in Florence, South Carolina (USA).
Under the terms of the purchase agreement, Patheon
will acquire the site for an immaterial sum, plus the cost of associated inventory and spare parts. Patheon
has also entered into a multi-year supply arrangement with Roche. Patheon
expects the supply agreement to help defray the costs associated with running the site for the next few years while it adds new client work into the facility. Over time, Patheon
expects the Florence facility to have a similar financial profile to its other sites in its drug substance segment.
will acquire the 300,000 sq ft facility with manufacturing capacity for APIs
ranging from development to manufacturing services. With the addition of this site, the company expands its capacity for manufacturing highly potent compounds, and adds capabilities to support solid-state chemistry, micronisation, and eventually, commercial spray drying.
“As the only end-to-end provider of pharma development and manufacturing services, Patheon
is uniquely positioned to integrate this new site into our global network and quickly leverage the capabilities with existing and new clients. The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals,” said James Mullen, CEO of Patheon.
The site features reactors ranging from 50-11,000 litres producing multiple products simultaneously, fully compliant with all applicable regulations, such as cGMP
(current good manufacturing practices) safety and environmental standards. It will provide Patheon
with a major US APIs
operation capable of supporting products from clinical scale to commercial manufacturing and further enhances its scientific and technical expertise.